Ranibizumab Biosimilar
Neovascular Age‑Related Macular Degeneration
ApprovedActive
Key Facts
About Biomm
Brazil’s leading biotech producing insulin and biosimilar biologics for oncology and ophthalmology.
View full company profileTherapeutic Areas
Other Neovascular Age‑Related Macular Degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| EY-002 | EyeYon Medical | Phase 1 |
| IBI302 | AP Biosciences | Phase 3 |